
DaVita (DVA) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
3.2B
Gross Profit
983.9M
30.52%
Operating Income
433.3M
13.44%
Net Income
232.2M
7.20%
EPS (Diluted)
$2.00
Balance Sheet Metrics
Total Assets
17.1B
Total Liabilities
15.5B
Shareholders Equity
1.7B
Debt to Equity
9.31
Cash Flow Metrics
Operating Cash Flow
287.9M
Free Cash Flow
36.8M
Revenue & Profitability Trend
DaVita Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 12.8B | 12.1B | 11.6B | 11.6B | 11.6B |
Cost of Goods Sold | 8.6B | 8.3B | 8.2B | 8.0B | 8.0B |
Gross Profit | 4.2B | 3.8B | 3.4B | 3.6B | 3.6B |
Gross Margin % | 32.9% | 31.5% | 29.3% | 31.4% | 30.8% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 1.5B | 1.5B | 1.4B | 1.2B | 1.2B |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 1.5B | 1.5B | 1.4B | 1.2B | 1.2B |
Operating Income | 2.0B | 1.6B | 1.3B | 1.8B | 1.7B |
Operating Margin % | 15.3% | 13.2% | 11.3% | 15.2% | 14.6% |
Non-Operating Items | |||||
Interest Income | - | - | - | - | - |
Interest Expense | 470.5M | 398.6M | 357.0M | 285.3M | 304.1M |
Other Non-Operating Income | 46.0M | -25.4M | 10.8M | 33.3M | -61.6M |
Pre-tax Income | 1.5B | 1.2B | 966.3M | 1.5B | 1.3B |
Income Tax | 279.7M | 220.1M | 198.1M | 306.7M | 313.9M |
Effective Tax Rate % | 18.3% | 18.7% | 20.5% | 20.2% | 23.8% |
Net Income | 1.3B | 957.0M | 781.6M | 1.2B | 994.7M |
Net Margin % | 9.8% | 7.9% | 6.7% | 10.4% | 8.6% |
Key Metrics | |||||
EBITDA | 2.6B | 2.4B | 2.1B | 2.5B | 2.4B |
EPS (Basic) | $11.02 | $7.62 | $6.03 | $9.30 | $6.46 |
EPS (Diluted) | $10.73 | $7.42 | $5.85 | $8.90 | $6.31 |
Basic Shares Outstanding | 84991000 | 90790000 | 92992000 | 105230000 | 119797000 |
Diluted Shares Outstanding | 84991000 | 90790000 | 92992000 | 105230000 | 119797000 |
Income Statement Trend
DaVita Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 794.9M | 380.1M | 244.1M | 461.9M | 325.0M |
Short-term Investments | 51.1M | 11.6M | 77.7M | 22.3M | 20.1M |
Accounts Receivable | 2.1B | 2.0B | 2.1B | 2.0B | 1.8B |
Inventory | 134.6M | 143.1M | 109.1M | 107.4M | 111.6M |
Other Current Assets | 122.9M | 102.6M | 78.8M | 72.5M | - |
Total Current Assets | 3.7B | 3.1B | 3.2B | 3.2B | 3.1B |
Non-Current Assets | |||||
Property, Plant & Equipment | 6.8B | 6.6B | 6.4B | 6.1B | 5.9B |
Goodwill | 14.9B | 14.4B | 14.3B | 14.3B | 14.0B |
Intangible Assets | 197.4M | 203.2M | 182.7M | 177.7M | 166.6M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 261.7M | 271.3M | 315.6M | 136.7M | 79.5M |
Total Non-Current Assets | 13.5B | 13.8B | 13.8B | 14.0B | 13.8B |
Total Assets | 17.3B | 16.9B | 16.9B | 17.1B | 17.0B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 547.2M | 514.5M | 479.8M | 402.0M | 434.3M |
Short-term Debt | 681.3M | 517.7M | 626.8M | 573.4M | 538.0M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 731.6M | 671.2M | 657.1M | 579.1M | 687.0M |
Total Current Liabilities | 3.0B | 2.6B | 2.6B | 2.4B | 2.5B |
Non-Current Liabilities | |||||
Long-term Debt | 11.4B | 10.6B | 11.2B | 11.4B | 10.7B |
Deferred Tax Liabilities | 665.4M | 726.2M | 782.8M | 831.0M | 809.6M |
Other Non-Current Liabilities | 169.6M | 183.1M | 105.2M | 119.2M | 150.1M |
Total Non-Current Liabilities | 12.2B | 11.5B | 12.1B | 12.4B | 11.6B |
Total Liabilities | 15.2B | 14.2B | 14.7B | 14.8B | 14.1B |
Equity | |||||
Common Stock | 90.0K | 89.0K | 90.0K | 97.0K | 110.0K |
Retained Earnings | 1.5B | 598.3M | 174.5M | 354.3M | 852.5M |
Treasury Stock | 1.4B | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 2.1B | 2.7B | 2.2B | 2.4B | 2.9B |
Key Metrics | |||||
Total Debt | 12.1B | 11.1B | 11.8B | 12.0B | 11.2B |
Working Capital | 772.7M | 495.7M | 535.5M | 769.2M | 672.6M |
Balance Sheet Composition
DaVita Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 1.3B | 957.0M | 781.6M | 1.2B | 994.7M |
Depreciation & Amortization | 723.9M | 745.4M | 732.6M | 680.6M | 630.4M |
Stock-Based Compensation | 102.8M | 112.4M | 95.4M | 102.2M | 91.5M |
Working Capital Changes | -29.8M | 194.5M | 101.0K | -140.6M | -104.2M |
Operating Cash Flow | 2.0B | 2.0B | 1.6B | 1.9B | 1.9B |
Investing Activities | |||||
Capital Expenditures | -555.4M | -568.0M | -603.4M | -641.5M | -674.5M |
Acquisitions | -251.3M | -302.6M | -89.2M | -201.0M | -204.4M |
Investment Purchases | -24.5M | -46.7M | -133.4M | -33.8M | -154.5M |
Investment Sales | 27.2M | 110.0M | 74.9M | 27.9M | 154.7M |
Investing Cash Flow | -778.1M | -776.7M | -634.3M | -787.7M | -828.5M |
Financing Activities | |||||
Share Repurchases | -1.4B | -320.3M | -839.6M | -1.6B | -1.5B |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 6.6B | 2.5B | 2.4B | 1.6B | 4.0B |
Debt Repayment | -5.5B | -3.0B | -2.4B | -861.1M | -4.1B |
Financing Cash Flow | -816.9M | -1.2B | -1.1B | -1.1B | -1.8B |
Free Cash Flow | 1.5B | 1.5B | 961.1M | 1.3B | 1.3B |
Net Change in Cash | 408.1M | 13.8M | -199.6M | 55.0M | -821.3M |
Cash Flow Trend
DaVita Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
13.45
Forward P/E
12.13
Price to Book
6.68
Price to Sales
0.74
PEG Ratio
5.74
Profitability Ratios
Profit Margin
6.35%
Operating Margin
15.70%
Return on Equity
57.94%
Return on Assets
7.15%
Financial Health
Current Ratio
1.39
Debt to Equity
825.19
Beta
1.09
Per Share Data
EPS (TTM)
$10.16
Book Value per Share
$-4.98
Revenue per Share
$164.22
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
dva | 9.8B | 13.45 | 6.68 | 57.94% | 6.35% | 825.19 |
HCA Healthcare | 94.2B | 16.91 | -76.81 | 13,631.68% | 8.21% | -37.45 |
Tenet Healthcare | 15.7B | 11.18 | 4.20 | 29.65% | 7.18% | 158.70 |
Ensign Group | 9.6B | 30.10 | 4.72 | 17.54% | 7.00% | 100.93 |
Chemed | 6.5B | 22.88 | 5.39 | 24.14% | 11.56% | 12.15 |
Option Care Health | 4.6B | 22.37 | 3.36 | 15.25% | 3.93% | 90.35 |
Financial data is updated regularly. All figures are in the company's reporting currency.